Krystal Biotech, Inc. Litigation Settlement, Expense
Krystal Biotech, Inc. (KRYS) reported Litigation Settlement, Expense of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LitigationSettlementExpense · last filed 2026-02-17
- Krystal Biotech, Inc. litigation settlement, expense for the quarter ending 2025-12-31 was $0.00.
- Krystal Biotech, Inc. litigation settlement, expense for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Krystal Biotech, Inc. litigation settlement, expense for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Krystal Biotech, Inc. litigation settlement, expense for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Krystal Biotech, Inc. litigation settlement, expense for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Krystal Biotech, Inc. litigation settlement, expense for fiscal 2024 was $37.50M, a 200.00% increase from fiscal 2023.
- Krystal Biotech, Inc. litigation settlement, expense for fiscal 2023 was $12.50M, a 50.00% decline from fiscal 2022.
- Krystal Biotech, Inc. litigation settlement, expense for fiscal 2022 was $25.00M.
| Period end | Litigation Settlement, Expense 3 month | Litigation Settlement, Expense 6 month | Litigation Settlement, Expense 9 month | Litigation Settlement, Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $0.00 derived: sum of 2 quarters · filed 2026-02-17 | $0.00 derived: sum of 3 quarters · filed 2026-02-17 | $0.00 10-K · filed 2026-02-17 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-03 | $0.00 derived: sum of 2 quarters · filed 2025-11-03 | $0.00 10-Q · filed 2025-11-03 | $0.00 derived: sum of 4 quarters · filed 2026-02-17 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-04 | $0.00 10-Q · filed 2025-08-04 | $0.00 derived: sum of 3 quarters · filed 2026-02-17 | $12.50M derived: sum of 4 quarters · filed 2026-02-17 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-06 | $0.00 derived: sum of 2 quarters · filed 2026-02-17 | $12.50M derived: sum of 3 quarters · filed 2026-02-17 | $25.00M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $12.50M derived: sum of 2 quarters · filed 2026-02-17 | $25.00M derived: sum of 3 quarters · filed 2026-02-17 | $37.50M 10-K · filed 2026-02-17 |
| 2024-09-30 | $12.50M 10-Q · filed 2025-11-03 | $25.00M derived: sum of 2 quarters · filed 2025-11-03 | $37.50M 10-Q · filed 2025-11-03 | $37.50M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $12.50M 10-Q · filed 2025-08-04 | $25.00M 10-Q · filed 2025-08-04 | $25.00M derived: sum of 3 quarters · filed 2026-02-17 | $25.00M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $12.50M 10-Q · filed 2025-05-06 | $12.50M derived: sum of 2 quarters · filed 2026-02-17 | $12.50M derived: sum of 3 quarters · filed 2026-02-17 | $12.50M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $0.00 derived: sum of 2 quarters · filed 2026-02-17 | $0.00 derived: sum of 3 quarters · filed 2026-02-17 | $12.50M 10-K · filed 2026-02-17 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-04 | $0.00 derived: sum of 2 quarters · filed 2024-11-04 | $12.50M 10-Q · filed 2024-11-04 | $12.50M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-05 | $12.50M 10-Q · filed 2024-08-05 | $12.50M derived: sum of 3 quarters · filed 2025-02-19 | $12.50M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-03-31 | $12.50M 10-Q · filed 2024-05-06 | $12.50M derived: sum of 2 quarters · filed 2025-02-19 | $12.50M derived: sum of 3 quarters · filed 2025-02-19 | $12.50M derived: sum of 4 quarters · filed 2025-02-19 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $0.00 derived: sum of 2 quarters · filed 2025-02-19 | $0.00 derived: sum of 3 quarters · filed 2025-02-19 | $25.00M 10-K · filed 2025-02-19 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-06 | $0.00 derived: sum of 2 quarters · filed 2023-11-06 | $25.00M 10-Q · filed 2023-11-06 | $25.00M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-07 | $25.00M 10-Q · filed 2023-08-07 | $25.00M derived: sum of 3 quarters · filed 2024-02-26 | $25.00M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $25.00M 10-Q · filed 2023-05-08 | $25.00M derived: sum of 2 quarters · filed 2024-02-26 | $25.00M derived: sum of 3 quarters · filed 2024-02-26 | $25.00M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $0.00 derived: sum of 2 quarters · filed 2024-02-26 | $0.00 derived: sum of 3 quarters · filed 2024-02-26 | $0.00 10-K · filed 2024-02-26 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-07 | $0.00 derived: sum of 2 quarters · filed 2022-11-07 | $0.00 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-08 | $0.00 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |